Health
bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization – Business Wire
Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary
MARCY LÉTOILE, France–(BUSINESS WIRE)–Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause…
-
Noosa News14 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business16 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
Noosa News15 hours agoBrisbane news live: 80,000 green bins rolled out | Residents told to prepare for ‘violent’ summer storms | Council declares water safe for swimming despite dead fish
-
General15 hours agoDay of pain: sirens ring out to mark attack on Israel